Reid Merryman, MD

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.